What happened to VIM thalamotomy for Parkinson's disease?

Area of Science:

• Neurosurgery
• Neurology
• Movement Disorders

Background:

• Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor symptoms like tremor, rigidity, and bradykinesia.
• Levodopa (L-dopa) is a primary treatment, but its efficacy diminishes over time, leading to drug-resistant symptoms.
• Thalamotomy, a surgical intervention, has been explored for managing severe, medication-refractory PD symptoms.

Purpose of the Study:

• To evaluate the long-term efficacy and safety of unilateral thalamotomy in patients with Parkinson's disease.
• To assess the impact of thalamotomy on various motor symptoms, including tremor, rigidity, and dexterity.
• To compare outcomes across different eras of L-dopa treatment.

Main Methods:

• A prospective review of 75 Parkinson's disease patients undergoing unilateral thalamotomy.
• Analysis of patient data from pre-operative, early L-dopa, and late L-dopa eras.
• Computer graphics used to examine functional changes, with histograms and scattergrams for performance evaluation up to 2 years post-surgery.

Main Results:

• Significant reduction in contralateral tremor was observed in 82% of patients 2 years post-surgery.
• No ipsilateral effects or consistent iatrogenic deterioration of function were identified.
• Improvements in rigidity and manual dexterity were less pronounced; locomotion, speech, facial movement, and handwriting did not improve.
• No mortality was recorded, but 8% of patients experienced persistent significant complications.

Conclusions:

• VIM thalamotomy is an effective treatment for severe, drug-resistant parkinsonian tremor.
• The procedure offers significant tremor relief with a low risk of mortality.
• While tremor is substantially improved, other motor symptoms show limited benefit, highlighting the selective efficacy of thalamotomy.